Biomarker-Based Prediction of Tyrosine Kinase Inhibitor Cardiotoxicity using Human iPSC-Derived Cardiomyocytes
Presented by Jessica Palmer at the Safety Pharmacology Society Meeting in Barcelona, Spain (September, 2019)
This study evaluated the utility of Stemina’s Cardio quickPredict assay for evaluating the cardiotoxicity potential of target kinase inhibitors (TKI). We tested 10 TKIs that induce a variety of cardiotoxic effects, including eight drugs clinically associated with cardiotoxicity (crizotinib, dasatinib, imatinib, lapatinib, nilotinib, sorafenib, sunitinib, and vandetanib) and two drugs considered to be relatively cardiac-safe (axitinib and erlotinib) to compare changes in metabolism of the PM ratios analyzed.
Stemina’s Cardio quickPredict assay accurately identified the cardiotoxicity potential for 9 of the 10 TKI evaluated in this study. It has greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.